- Home
- FGBI vs PRLD Comparison
FGBI vs PRLD Comparison
Compare FGBI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGBI | PRLD |
|---|---|---|
| Founded | 1934 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FGBI | PRLD |
|---|---|---|
| Price | $4.79 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 24.3K | ★ 514.2K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,036,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $4.31 | $0.61 |
| 52 Week High | $14.93 | $4.22 |
Technical Indicators
Market Signals| Indicator | FGBI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 48.60 |
| Support Level | $4.31 | $1.30 |
| Resistance Level | $5.17 | $1.56 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 43.44 | 41.38 |
Price Performance
Historical ComparisonAbout FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.